<DOC>
	<DOCNO>NCT02641002</DOCNO>
	<brief_summary>Study CC-90002-AML-001 open-label , Phase 1 dose escalation ( Part A ) expansion ( Part B ) , clinical study CC-90002 , administer intravenous ( IV ) infusion , subject relapse and/or primary refractory AML high-risk MDS . The study explore escalating dos CC-90002 use 3 + 3 dose escalation design Part A , follow dose expansion Part B . The primary objective determine safety tolerability CC-90002 also define non-tolerated dose ( NTD ) , maximum tolerate dose ( MTD ) and/or recommend Phase 2 dose ( RP2D ) CC-90002 .</brief_summary>
	<brief_title>A Study CC-90002 Subjects With Acute Myeloid Leukemia ( AML ) High-risk Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>In Part A Part B , treatment administer two phase start induction phase follow maintenance phase . During induction phase , treatment administer 42-day cycle Cycles 1 4 . Following completion Cycle 4 induction phase , subject non-progressive disease enter maintenance phase . During maintenance phase , treatment administer 28 day cycle . Subjects may continue CC-90002 maximum 2 year ( eg , induction phase Cycles 1 4 maintenance phase Cycles 5 24 ) clinically significant disease progression , occurrence intolerable toxicity , physician/subject decision discontinue CC-90002 , whichever come first .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1 . Men woman ≥ 18 year age , time signing informed consent form ( ICF ) . 2 . Relapsed and/or primary refractory Acute Myeloid Leukemia ( AML ) Myelodysplastic Syndrome ( MDS ) subtype refractory anemia excess blast ( RAEB ) 2 define high highrisk recurrent refractory , patient intolerant establish therapy . 3 . Subject consent hospitalization first ( Cycle 1 Day 1 ) dose CC90002 72 hour . 4 . Subject consent serial bone marrow aspiration biopsy specify . 5 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 2 . 6 . Eligible study subject must exhibit acceptable liver , renal , coagulation function assess laboratory test . 7 . Females male must practice true abstinence agree contraceptive method throughout study , 8 week follow last dose CC 90002 . 1 . Active central nervous system ( CNS ) leukemia know CNS leukemia . 2 . Immediately lifethreatening , severe complication leukemia . 3 . Impaired cardiac function clinically significant cardiac disease . 4 . Glucose6phosphate dehydrogenase ( G6PD ) deficiency . 5 . Prior autologous hematopoietic stem cell transplant ≤ 3 month . 6 . Prior allogeneic hematopoietic stem cell transplant ( HSCT ) either standard reduce intensity condition ≤ 6 month . 7 . Systemic immunosuppressive therapy post HSCT clinically significant graftversushost disease ( GVHD ) . 8 . Prior systemic cancerdirected treatment investigational modality ≤ 5 half live 4 week whichever short . 9 . Major surgery ≤ 2 week recover clinically significant effect recent surgery . 10 . Pregnant nursing female . 11 . Known HIV infection . 12 . Known chronic hepatitis B C ( HBV/HCV ) infection . 13 . Ongoing treatment chronic , therapeutic dosing anticoagulant . 14 . History autoimmune hemolytic anemia autoimmune thrombocytopenia . 15 . History concurrent second cancer require active , ongoing systemic treatment . 16 . Subjects potentially curative anticancer therapy available .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>CC-90002</keyword>
	<keyword>Monoclonal</keyword>
	<keyword>Antibody</keyword>
	<keyword>CD47</keyword>
	<keyword>Hematologic Cancers</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Blood disorder</keyword>
</DOC>